---
title: "Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286637608.md"
description: "ARS Pharmaceuticals (SPRY) reported regulatory wins for needle-free epinephrine neffy in Mar–Apr 2026: FDA removed minimum age, Health Canada approved, and EU granted marketing authorization.1ARS Pharmaceuticals (SPRY) Q1 2026 revenue $22.68–22.7M (+184% YoY) from U.S. neffy sales, access programs, and collaborations; GAAP net loss $60.62M; adj. loss/shr $0.61; stock -31.8% YTD.23"
datetime: "2026-05-16T07:14:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286637608.md)
  - [en](https://longbridge.com/en/news/286637608.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286637608.md)
---

# Key facts: ARS neffy approved US/Canada/EU; rev $22.7M, loss $60.6M

-   ARS Pharmaceuticals (SPRY) reported regulatory wins for needle-free epinephrine neffy in Mar–Apr 2026: FDA removed minimum age, Health Canada approved, and EU granted marketing authorization.1
-   ARS Pharmaceuticals (SPRY) Q1 2026 revenue $22.68–22.7M (+184% YoY) from U.S. neffy sales, access programs, and collaborations; GAAP net loss $60.62M; adj. loss/shr $0.61; stock -31.8% YTD.23

### Related Stocks

- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update | SPRY Stock News](https://longbridge.com/en/news/286543133.md)
- [ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion](https://longbridge.com/en/news/286552367.md)
- [ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth](https://longbridge.com/en/news/286545099.md)
- [09:51 ETIntroducing Spry PR: LANC Marketing Strides Ahead with New Brand Identity](https://longbridge.com/en/news/286925549.md)
- [ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales](https://longbridge.com/en/news/278370109.md)